Summary
This study investigated the changes of CD4+ CD25+ regulatory T cells (Tregs) in peripheral blood of patients with hepatocellular carcinoma before and after transcatheter arterial chemoembolization (TACE). The proportion of CD4+ CD25+ Tregs among CD4+ T lymphocytes in peripheral blood of 33 patients with hepatocellular carcinoma was determined by flow cytometry before, 1 week and 1 month after TACE. And 25 healthy volunteers served as control. One month after TACE, the patients were divided into two groups: 22 in group A, who were in stable condition or getting better; and 10 in group B, who were deteriorating. One patient died and was excluded. The results showed that the percentage of CD4+CD25+ Tregs among CD4+ T lymphocytes did not significantly change in the 33 patients 1 week after TACE as compared with that before TACE, however, the difference was significant (P<0.01) between the patients with hepatocellular carcinoma and the healthy subjects. The percentage of CD4+ CD25+ Tregs among CD4+ T lymphocytes in group A 1 month after TACE was decreased significantly in comparison with that before and 1 week after TACE (P<0.01), whereas, that in group B was increased significantly 1 month after TACE (P<0.01). It was concluded that patients with hepatocellular carcinoma had a higher proportion of CD4+CD25+ Tregs in peripheral blood. TACE did not significantly affect the level of CD4+ CD25+ Tregs within short time (such as 1 week). The proportion of CD4+CD25+ Tregs in peripheral blood 1 month after TACE was related to the prognosis of hepatocellular carcinoma.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cao M, Cabrera R, Xu Y et al. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+ CD25+ regulatory T cells. Lab Invest, 2007,87(6): 582–590
Sakaguchi S, Sakaguchi N, Asano M et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995,155:1151–1164
Woo E Y, Yeh H, Chu C S et al. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol, 2002,168:4272–4276
Dercamp C, Chemin K, Caux C et al. Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res, 2005,65:8479–8486
Unitt E, Rushbrook S M, Marshall A et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T-regulatory cells. Hepatology, 2005,41(4):722–730
Ghiringhelli F, Menard C, Terme M et al. CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor beta-dependent manner. J Exp Med, 2005,202:1075–1085
Ormandy L A, Hillemann T, Wedemeyer H et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res, 2005,65(6):2457–2464
Itoh M, Takahashi T, Sakaguchi N et al. Thymus and autoimmunity: production of CD4+ CD25+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol, 1999,162(2):5317–5326
Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell, 2000,101:455–458
Morse M A, Clay T M, Mosca P et al. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther, 2002,2:827–834
Sojka K D, Huang Y H, Fowell D J. Mechanisms of regulatory T-cell suppression—a diverse arsenal for a moving target. Immunology, 2008,14 (Epub ahead of print)
Menard C, Martin F, Apetoh L et al. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother, 2008, 28 (Epub ahead of print)
Woo E Y, Yeh H, Chu C S et al. Cutting Edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol, 2002,168:4272–4276
Curiel T, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 2004,10: 942–949
Miller A M, Lundberg K, Ozenci V et al. CD4+ CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol, 2006,177:7398–7405
Liyanage U K, Moore T T, Joo H G et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol, 2002,169:2756–2761
Hiraoka N, Onozato K, Kosuge T et al. Prevalence of FOXP3t regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res, 2006,12:5423–5434
Peng Q Q, Li S P, Xu L et al. Clinical Significance of the proportion of CD4+ CD25+ regulatory T cells in peripheral blood of hepatocellular carcinoma patients: A report of 117 cases. Chin J Cancer (Chinese), 2007,26(7):748–751
Sasaki A, Tanaka F, Mimori K et al. Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol, 2008,34(2):173–179
Author information
Authors and Affiliations
Additional information
Bin XIONG, male, born in 1975, Doctor in Charge
Rights and permissions
About this article
Cite this article
Xiong, B., Feng, G., Luo, S. et al. Changes of CD4+ CD25+ regulatory T cells in peripheral blood in patients with hepatocellular carcinoma before and after TACE. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 28, 645–648 (2008). https://doi.org/10.1007/s11596-008-0606-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-008-0606-7